Vivimed Labs Limited — Board Meeting, 13-11-2025: Outcome of Board Meeting

Vivimed Labs' board approved Q2/H1 consolidated results with a reported loss. Auditors issued a qualified opinion due to unrecorded interest of ₹30.71 Cr for H1, pushing the total loss to ₹43.51 Cr. Board also approved a pre-packaged insolvency process (shareholder approval pending) and expects trading suspension revocation.